Appeal No. 1996-0729
Application No. 07/859,572
1. A method for preventing or reversing the functional deficiency induced in
lymphoid cells during HIV infection or by exposure to HIV components, which method
comprises inhibiting the cAMP/PKA pathway of said cells by contacting said cells with
an amount of 2', 5'-dideoxyadenosine (ddAdo) effective to inhibit adenylate cyclase in
said cells.
7. A pharmaceutical composition useful for reversing the negative effect of
exposure to HIV components on lymphoid cell function, which composition comprises
an effective amount of 2', 5'-dideoxyadenosine (ddAdo) in admixture with at least one
pharmaceutically acceptable excipient.
12. A method to treat a subject infected with HIV, which method comprises
administering to said subject an amount of 2', 5'-dideoxyadenosine (ddAdo) effective to
inhibit the PKA/cAMP pathway in the lymphoid cells of said subject.
The examiner relies on the following references as evidence of obviousness:
Mitsuya et al. (Mitsuya) 4,861,759 Aug. 29, 1989
Ahluwalia et al. (Ahluwalia), 108 Chemical Abstracts, No. 31396m, page 27 (1988).
Harmenberg et al. (Harmenberg), 115 Chemical Abstracts, No. 150368h, page 84 (1991).
Herdewijn et al. (Herdewijn), 107 Chemical Abstracts, No. 176403a, page 764 (1987).
Legrand et al. (Legrand I), 113 Chemical Abstracts, No. 185172a, page 118 (1990).
Van Aerschot et al. (Van Aerschot), Chemical Abstracts, No. 58257r, page 810 (1989).
Legrand et al., (Legrand II), “Effects of Adenosine and Analogs on Adenylate Cyclase Activity in
Cultured Bovine Aortic Endothelial Cells,” 40 Biochemical Pharmacology, no. 5, 1990, 1103-1109.
- 2 -
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007